Fulgent Genetics, Inc.(FLGT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Fulgent Genetics, Inc. (FLGT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FLGT at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,734 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (9.2) and earnings quality (10.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Fulgent Genetics, Inc. reports quarterly revenue of $85.4M, net income of $-29.5M, an operating margin of -42.3%. Top institutional holders of FLGT by reported 13-F value include BlackRock, ACADIAN ASSET MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FLGT trades on the Nasdaq exchange and files with the SEC under CIK 1674930. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FLGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fulgent Genetics, Inc. directly from SEC EDGAR.